Altimmune, Inc.(ALT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALT Altimmune, Inc.

Post-Mkt 12-22 18:29:21 EST

4.14

+0.24

+6.15%

盘后4.15

+0.01+0.24%

18:23 EST

High4.45	Low3.95	Vol6.86M
Open3.96	D1 Closing3.90	Amplitude12.82%
Mkt Cap431.98M	Tradable Cap430.56M	Total Shares104.34M
T/O28.81M	T/O Rate6.60%	Tradable Shares104.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALT","market":"US","secType":"STK","nameCN":"Altimmune, Inc.","latestPrice":4.14,"timestamp":1766437200000,"preClose":3.9,"halted":0,"volume":6861325,"hourTrading":{"tag":"盘后","latestPrice":4.15,"preClose":4.14,"latestTime":"18:23 EST","volume":39057,"amount":165929.680686,"timestamp":1766445827115},"delay":0,"floatShares":104000000,"shares":104342385,"eps":-1.056106,"marketStatus":"Post-Mkt","change":0.24,"latestTime":"12-22 18:29:21 EST","open":3.96,"high":4.45,"low":3.95,"amount":28813907.913775,"amplitude":0.128205,"askPrice":4.2,"askSize":10,"bidPrice":4.15,"bidSize":361,"shortable":0,"etf":0,"ttmEps":-1.056106,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1766451600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":3.9,"preHourTrading":{"tag":"盘前","latestPrice":3.9506,"preClose":3.9,"latestTime":"09:29 EST","volume":86303,"amount":340073.0188226,"timestamp":1766413794315},"postHourTrading":{"tag":"盘后","latestPrice":4.15,"preClose":4.14,"latestTime":"18:23 EST","volume":39057,"amount":165929.680686,"timestamp":1766445827115},"volumeRatio":0.937665,"impliedVol":0.9471,"impliedVolPercentile":0.356},"requestUrl":"/m/hq/s/ALT","defaultTab":"news","newsList":[{"id":"2593458649","title":"Altimmune Director Jerome Benedict Durso Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2593458649","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/2593458649?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:11","pubTimestamp":1766437876,"startTime":"0","endTime":"0","summary":"Jerome Benedict Durso, a Director at Altimmune Inc., has reported the acquisition of common shares of Altimmune Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 22, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL7CxnNg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Altimmune Director Jerome Benedict Durso Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALT","LU1878469433.USD","BK4599","BK4139"],"gpt_icon":0},{"id":"2592160651","title":"BUZZ-U.S. STOCKS ON THE MOVE-Intuitive Machines, Palo Alto Networks, Redwire","url":"https://stock-news.laohu8.com/highlight/detail?id=2592160651","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592160651?lang=en_us&edition=fundamental","pubTime":"2025-12-19 22:09","pubTimestamp":1766153366,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Intuitive Machines, Palo Alto Networks,RedwireEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nL6N3XP0LF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","LU1169589451.USD","NVDS","SNVD.UK","NVD","RDW","LU1868836914.USD","NVDS.UK","MRK","BTBT","ETN","ALT","NVD2.UK","LU1821325948.USD","LU2264538146.SGD","PCAR","NVIW.SI","LU1691799644.USD","EVAX","NVDX","LMT","2NVD.UK","LU1868837136.USD","LUNR","LU1868836591.USD","LYFT","IE00BFXG0V08.USD","BK4535","NVDY","RIOT","WYFI","BA","UUUU","NVD3.UK","NVDU","PANW","LU2756315664.SGD","3NVD.UK","NVDD","AGCO","ACN"],"gpt_icon":1},{"id":"2592744166","title":"Altimmune's drug for a type of liver disease shows benefits in mid-stage study","url":"https://stock-news.laohu8.com/highlight/detail?id=2592744166","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592744166?lang=en_us&edition=fundamental","pubTime":"2025-12-19 19:39","pubTimestamp":1766144362,"startTime":"0","endTime":"0","summary":"Altimmune's drug for a type of liver disease shows benefits in mid-stage studyDec 19 (Reuters) - Altimmune ALT.O said on Friday its experimental drug improved signs of liver scarring and liver health ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nL4N3XP0UR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4599","ALT","LU1878469433.USD"],"gpt_icon":0},{"id":"2592166417","title":"Altimmune Shares Climb 6.9% Premarket After Positive Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2592166417","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592166417?lang=en_us&edition=fundamental","pubTime":"2025-12-19 19:35","pubTimestamp":1766144153,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nFWN3XP0E5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALT","LU1878469433.USD","BK4599","BK4139"],"gpt_icon":0},{"id":"2592166178","title":"Altimmune Reports Positive 48-Week Phase 2b Results for Pemvidutide in MASH Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592166178","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592166178?lang=en_us&edition=fundamental","pubTime":"2025-12-19 19:30","pubTimestamp":1766143823,"startTime":"0","endTime":"0","summary":"Altimmune Inc. announced positive topline results from the IMPACT Phase 2b trial of pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, in patients with metabolic dysfunction-associated steatohepatitis  at 48 weeks. The trial demonstrated improvements in key non-invasive markers of fibrosis across treatment arms compared to placebo, with continued reductions from the 24-week timepoint. Additional weight loss was observed from 24 to 48 weeks with the 1.8 mg dose, without plateauing. Pemvidutide maintained a favorable tolerability profile at 48 weeks, with a low treatment-related discontinuation rate. Following an end-of-Phase 2 meeting with the FDA, Altimmune plans to advance pemvidutide to a registrational Phase 3 trial in MASH patients with moderate to advanced liver fibrosis, expected to begin in 2026. The 48-week Phase 2b data were presented during a conference call and webcast on December 19, 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL67VzZP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1878469433.USD","SG9999014039.USD","LU2095319765.USD","BK4139","IE00BKPKM429.USD","BK4588","LU2210150020.SGD","BK4112","IE00B64PRP62.GBP","SG9999014013.SGD","IE00BGHQF748.EUR","BK4599","SG9999014021.USD","ALT","SG9999014005.SGD","LU0314104364.USD","LU2210149790.SGD","NDAQ","BK4585","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2592516615","title":"Altimmune Inc - Pemvidutide 1.8 Mg Dose Achieves 7.5% Weight Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2592516615","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592516615?lang=en_us&edition=fundamental","pubTime":"2025-12-19 19:30","pubTimestamp":1766143800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nTUA3FYZSR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4599","ALT","LU1878469433.USD"],"gpt_icon":0},{"id":"2592166165","title":"Altimmune Announces That Pemvidutide Achieved Key Measures of Success at 48 Weeks in Impact Phase 2B Mash Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592166165","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592166165?lang=en_us&edition=fundamental","pubTime":"2025-12-19 19:30","pubTimestamp":1766143800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nTUA3FYZSR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1878469433.USD","ALT","BK4139","BK4599"],"gpt_icon":0},{"id":"2590505982","title":"FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up","url":"https://stock-news.laohu8.com/highlight/detail?id=2590505982","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590505982?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:04","pubTimestamp":1765541041,"startTime":"0","endTime":"0","summary":"FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats upChanges dateline, adds new details in paragraph 19, 20, 27, 36 and 54. The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently dominated by Novo Nordisk NOVOb.CO and Eli Lilly LLY.N.Analysts project the industry could rake in $150 billion in annual sales by the next decade.Soaring demand for its obesity treatment has helped Lilly become the first pharmaceutical company to reach","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nL4N3XI0R0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN8TJ469.HKD","IE0002141913.USD","IE0005OL40V9.USD","IE00BK4W5M84.HKD","SRRK","SG9999015986.USD","LU2106854487.HKD","03933","03692","LU0345777147.USD","AZN.UK","SG9999013999.USD","ALT","BK4566","LLY","600196","SG9999014906.USD","LU0306806265.USD","IE00BJJMRX11.SGD","BK0187","LU1061106388.HKD","MTSR","LU0106261372.USD","AMGN","MRK","LU0130517989.USD","SG9999002224.SGD","LU0256863902.USD","LU0211328371.USD","VKTX","LU1323610961.USD","LU0964806797.USD","LU1003077747.HKD","LU1035775433.USD","IE00BJLML261.HKD","00656","LU1720051017.SGD","BK0188","GPCR","SGXZ99366536.SGD","03165","LU0823434583.USD","OPK","LU1989772840.SGD","BK0028","IE00B4JS1V06.HKD","LU0499090636.EUR","LU1989771016.USD","02105"],"gpt_icon":1},{"id":"2588774604","title":"BUZZ-U.S. STOCKS ON THE MOVE-Ideaya Biosciences, Omnicom Group, Targa Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2588774604","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588774604?lang=en_us&edition=fundamental","pubTime":"2025-12-02 00:53","pubTimestamp":1764607982,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Ideaya Biosciences, Omnicom Group, Targa ResourcesEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nL6N3X70KP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLNE","USAC","NVAX","NVDS","CPNG","HL","MRNA","TRGP","DARE","FLYE","OMC","FCEL","LUV","ACN","ALT","FANG","UAL","IDYA","INR","NVDY","BLTE","KGS","PAVS","LEG","AHMA","ZS","QTTB","TSYW.SI","IDA","CDE","NVDD","ODFL","SNPS","NVDU","EXC","AAL"],"gpt_icon":1},{"id":"2588778560","title":"Altimmune CEO Vipin Garg to Step Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2588778560","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588778560?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:25","pubTimestamp":1764595547,"startTime":"0","endTime":"0","summary":"Altimmune  said Monday that Vipin Garg will step down as the company's president and chief executive officer, starting Jan. 1. 2026.Following the move, Jerry Durso, Altimmune's chairman of the board, will assume the role of president and CEO and retain his position as chairman, the company said.Garg will continue to serve as an advisor to the company through June 30, 2026, Altimmune said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1878469433.USD","BK4139","BK4599","ALT"],"gpt_icon":0},{"id":"2588727489","title":"BUZZ-Altimmune falls as CEO Vipin Garg to step down","url":"https://stock-news.laohu8.com/highlight/detail?id=2588727489","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588727489?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:47","pubTimestamp":1764593270,"startTime":"0","endTime":"0","summary":"BUZZ-Altimmune falls as CEO Vipin Garg to step down** Shares of drug developer Altimmune ALT.O fall 6.7% to $4.91 premarket** Co says Chairman Jerry Durso will take over as chief executive officer on January 1, 2026, succeeding Vipin Garg, who has led the company for seven years** Co says Durso previously led Intercept Pharmaceuticals and spent over 20 years at Sanofi SASY.PA ** Co's lead drug pemvidutide is being developed for liver disease and weight loss - ALT** ALT expects 48-week mid-stage trial data and FDA meeting on proposed late-stage study before year-end, co says** Up to last close, stock down ~27% YTD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nL4N3X70YZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1878469433.USD","BK4599","BK4139","ALT"],"gpt_icon":0},{"id":"2588273707","title":"BRIEF-Altimmune Announces CEO Transition, Succession Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2588273707","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588273707?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:38","pubTimestamp":1764592705,"startTime":"0","endTime":"0","summary":"BRIEF-Altimmune Announces CEO Transition, Succession PlanDec 1 (Reuters) - Altimmune Inc ALT.O:ALTIMMUNE ANNOUNCES CEO TRANSITION AND SUCCESSION PLANALTIMMUNE INC - JERRY DURSO TO SUCCEED VIPIN GARG A","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA4QRGV8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALT","BK4139","LU1878469433.USD","BK4599"],"gpt_icon":0},{"id":"2588722025","title":"Altimmune Inc - Vipin Garg to Step Down as CEO Effective Jan 1, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588722025","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588722025?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:30","pubTimestamp":1764592201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA4QRGV8:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU1878469433.USD","ALT","BK4599"],"gpt_icon":0},{"id":"2588722010","title":"Altimmune Inc - Vipin Garg to Serve as Advisor Through June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588722010","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588722010?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:30","pubTimestamp":1764592201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA4QRGV8:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU1878469433.USD","BK4599","ALT"],"gpt_icon":0},{"id":"2588220267","title":"Altimmune Inc - Jerry Durso to Assume Role of CEO and Retain Chairman Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2588220267","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588220267?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:30","pubTimestamp":1764592201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA4QRGV8:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALT","BK4139","LU1878469433.USD","BK4599"],"gpt_icon":0},{"id":"2588727863","title":"Press Release: Altimmune Announces CEO Transition and Succession Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2588727863","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588727863?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:30","pubTimestamp":1764592200,"startTime":"0","endTime":"0","summary":"Jerry Durso, accomplished industry leader, to succeed Vipin Garg, Ph.D. as Chief Executive Officer. Transition follows seven years of strong leadership by Dr. Garg. GAITHERSBURG, Md., Dec. 01, 2025  -- Altimmune, Inc. , a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and metabolic diseases, today announced a CEO succession plan under which Vipin Garg, Ph.D. will step down as the Company's President and Chief Executive Officer effective January 1, 2026. Altimmune's Chairman of the Board, Jerry Durso, will assume the role of President and Chief Executive Officer and retain his position as Chairman. To facilitate a smooth transition, Dr. Garg will serve as an advisor to the Company through June 30, 2026.\"I am very excited to step into the role of CEO as Altimmune embarks on its next phase of growth and prepares to transition to a late-stage clinical company looking toward commercialization. I see significant potential for pemvidutide t","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALT","ALD","LU1878469433.USD","BK4139","BK4599"],"gpt_icon":0},{"id":"2586724475","title":"FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up","url":"https://stock-news.laohu8.com/highlight/detail?id=2586724475","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586724475?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:39","pubTimestamp":1764077944,"startTime":"0","endTime":"0","summary":"FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats upRewrites paragraph 1, adds Lilly valuation milestone in paragraph 3, updates with Novo trial details in paragraphs 9-0. Promising results of Novo Nordisk's NOVOb.CO experimental obesity drug, amycretin, from a mid-stage trial could give the drugmaker much-needed heft to reclaim lost ground in the weight-loss market, which is projected to reach $150 billion by next decade.Novo said the drug appeared safe and well tolerated, with mostly mild-to-moderate gastrointestinal side effects. Late-stage trials are planned for 2026. Amycretin has a dual-mode action, targeting GLP-1 and amylin hormones.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nL4N3X10QM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRRK","LU0079474960.USD","03933","LU0094547139.USD","LU0557290698.USD","LU0820561909.HKD","LU0225771236.USD","02105","LU0265550359.USD","LU1066051225.USD","SG9999011175.SGD","VKTX","LU2168564149.EUR","AMGN","IE0004445239.USD","LU0109391861.USD","LU2746668461.USD","AZN.UK","LU1057294990.SGD","LU0738911758.USD","SG9999013999.USD","IE00B4R5TH58.HKD","BK4592","LU0353189680.USD","LU2168563687.JPY","ALT","LU2265009873.SGD","SG9999014542.SGD","LU0198837287.USD","LU0823416689.USD","IE00BLSP4239.USD","03692","SG9999015986.USD","GPCR","LU2168564065.EUR","LU1061106388.HKD","03165","LU1551013342.USD","LU2063271972.USD","MRK","LU0949170772.SGD","OPK","LU1023059063.AUD","LU1069347547.HKD","SG9999015945.SGD","LU0964806797.USD","LU0553294199.USD","MTSR"],"gpt_icon":1},{"id":"2584299759","title":"Altimmune Inc Files For Mixed Shelf Of Up To $400 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584299759","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584299759?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:00","pubTimestamp":1763571611,"startTime":"0","endTime":"0","summary":"Nov 7 (Reuters) - Altimmune Inc ::*ALTIMMUNE INC FILES FOR MIXED SHELF OF UP TO $400 MILLION - SEC FILING  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202523:04:44 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD2hFfPv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALT","LU1878469433.USD","BK4599"],"gpt_icon":0},{"id":"2584926282","title":"Altimmune Amends Loan And Security Agreement With Hercules Capital - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584926282","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584926282?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:53","pubTimestamp":1763571231,"startTime":"0","endTime":"0","summary":"Nov 6 (Reuters) - Altimmune Inc ::*ALTIMMUNE INC - AMENDS LOAN AND SECURITY AGREEMENT WITH HERCULES CAPITAL - SEC FILING*ALTIMMUNE INC - TERM LOAN INCREASED FROM $100 MILLION TO $125 MILLION - SEC FIL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD8QhGjf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALT","HTGC","LU1878469433.USD","BK4599","BK4139","BK4135"],"gpt_icon":0},{"id":"2584944390","title":"TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies","url":"https://stock-news.laohu8.com/highlight/detail?id=2584944390","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584944390?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:30","pubTimestamp":1763559000,"startTime":"0","endTime":"0","summary":"NEW YORK, Nov.  19, 2025  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX),today announced it ranked number 27 on the Deloitte Technology Fast 500, a ranking of the 500 fastest-growing technol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/19/3190944/8790/en/TG-Therapeutics-Makes-2025-Deloitte-Technology-Fast-500-List-of-America-s-Fastest-Growing-Companies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1732800096.USD","LU0882574139.USD","BK4599","PML","BK4504","LU1244550577.SGD","BK4139","LU1720051108.HKD","LU1878469433.USD","LU2023251221.USD","TGTX","LU0528227936.USD","BK4135","LU0267386448.USD","LU1989772840.SGD","LU0225283273.USD","BK4090","BK4585","LU0158827781.USD","CNS","IE00B5TLWC47.USD","LU1668664300.SGD","BK4104","LU0006306889.USD","LU2271345857.HKD","LU1244550494.USD","TG","HCP","IE00BZ1G4Q59.USD","LU1363072403.SGD","IE00BKVL7J92.USD","FAST","LU0795875169.SGD","LU0158827948.USD","LU1732799900.SGD","LU1162221912.USD","ALT","LU2089284900.SGD","BK4588","BK4534","BK4567","BK4516","LU0098860793.USD","LU1074936037.SGD","LU0557290698.USD","LU0106261372.USD","IE00BYQQ9H92.USD","LU2111349929.HKD","BK4127","LU1989772923.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.altimmune.com","stockEarnings":[{"period":"1week","weight":-0.26},{"period":"1month","weight":-0.1503},{"period":"3month","weight":0.0317},{"period":"6month","weight":-0.4452},{"period":"1year","weight":-0.5232},{"period":"ytd","weight":-0.4591}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.388889,"avgChangeRate":-0.008115},{"month":2,"riseRate":0.388889,"avgChangeRate":0.000059},{"month":3,"riseRate":0.388889,"avgChangeRate":-0.052418},{"month":4,"riseRate":0.388889,"avgChangeRate":-0.049636},{"month":5,"riseRate":0.5,"avgChangeRate":0.064208},{"month":6,"riseRate":0.388889,"avgChangeRate":-0.000157},{"month":7,"riseRate":0.388889,"avgChangeRate":0.041853},{"month":8,"riseRate":0.444444,"avgChangeRate":0.10411},{"month":9,"riseRate":0.210526,"avgChangeRate":-0.115822},{"month":10,"riseRate":0.263158,"avgChangeRate":0.032599},{"month":11,"riseRate":0.421053,"avgChangeRate":-0.007448},{"month":12,"riseRate":0.526316,"avgChangeRate":0.187177}],"exchange":"NASDAQ","name":"Altimmune, Inc.","nameEN":"Altimmune, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Altimmune, Inc.(ALT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Altimmune, Inc.(ALT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Altimmune, Inc.,ALT,Altimmune, Inc.股票,Altimmune, Inc.股票老虎,Altimmune, Inc.股票老虎国际,Altimmune, Inc.行情,Altimmune, Inc.股票行情,Altimmune, Inc.股价,Altimmune, Inc.股市,Altimmune, Inc.股票价格,Altimmune, Inc.股票交易,Altimmune, Inc.股票购买,Altimmune, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Altimmune, Inc.(ALT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Altimmune, Inc.(ALT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction